• E. W. Stalman
  • L. Y. L. Kummer
  • P. J. van Dam
  • A. G. Volkers
  • L. Boekel
  • A. A. Toorop
  • E. M. M. Strijbis
  • C. van Sandt
  • N. J. M. Verstegen
  • M. Steenhuis
  • J. Killestein
Original languageEnglish
Article number103416
JournalMULTIPLE SCLEROSIS AND RELATED DISORDERS
Volume57
DOIs
Publication statusPublished - 1 Jan 2022

    Research areas

  • Antibodies, COVID-19, Multiple sclerosis, Ocrelizumab, SARS-CoV-2

ID: 20637646